OrthoNeutrogena(R), the dermatology-specialty division of Johnson & Johnson, is a leader in delivering novel therapies that address the multiple needs of dermatologists and their patients. A pioneer in treatment areas that span from acne and infection to aesthetics and photodamage, OrthoNeutrogena continues to demonstrate an unwavering commitment to the dermatology community. OrthoNeutrogena dermatology products include: RETIN-A MICRO(R) PUMP, ERTACZO(R), BIAFINE(R), RENOVA(R) and Grifulvin V(R).
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov or on request from Johnson & Johnson. Johnson & Johnson assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.)
About ELLEgirl.com
ELLEgirl.com provides young women with insider information on fashion,
beauty, service
'/>"/>
| SOURCE OrthoNeutrogena Copyright©2008 PR Newswire. All rights reserved |